

Special Issue

New Therapeutic Strategies in Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer is currently the third leading cause of cancer-related death and is estimated to become the second leading cause within the next decade. The current treatment for patients for both local and metastatic disease is a combination of chemotherapeutic agents. Pancreatic cancer presents frequent alterations in oncogenes or tumor suppressor genes such as KRAS, TP53, SMAD4, and CDKN2A. Further studies to test novel agents that specifically target these altered signaling pathways will be critical for the design of new therapeutic strategies. These novel agents will probably need to be used as part of combination approaches with a standard chemotherapeutic regimen or with an immunotherapy approach to prevent early resistance mechanisms from emerging. These new advances should achieve considerable survival benefits with reduced side effects and mortality of patients with pancreatic cancer. This Special Issue aims to publish original research or reviews concerning the treatment options for pancreatic cancers, highlighting new advances in this field.

Guest Editor

Dr. Graziana Digiacomio

Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy

Deadline for manuscript submissions

closed (20 January 2022)



Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/81642

Life
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/

[life](https://life.mdpi.com)





Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
life](https://mdpi.com/journal/life)



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona
Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)